These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4170420)

  • 21. Nonsurgical treatment of human benign prostatic hyperplasia.
    Scott WW; Coffey DS
    Vitam Horm; 1975; 33():439-65. PubMed ID: 59463
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of a novel nonsteroidal antiandrogen on canine prostatic hyperplasia.
    Neri RO; Monahan M
    Invest Urol; 1972 Sep; 10(2):123-30. PubMed ID: 4116667
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of anti-androgen (TZP-4238) on steroid-induced canine prostatic hyperplasia. Light and electron microscopic investigations.
    Murakoshi M; Inada R; Makino M; Suzuki M; Mieda M; Honma S; Yamanaka H
    Acta Pathol Jpn; 1990 Dec; 40(12):871-9. PubMed ID: 1710865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiandrogens and prostatic tumours (experimental base and clinical use).
    Neumann R; Schenck B; Senge T; Richter KD
    Prog Clin Biol Res; 1976; 6():169-88. PubMed ID: 66688
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH).
    Geller J; Albert J
    Urol Res; 1987; 15(3):151-3. PubMed ID: 3629749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon].
    Sivkov AV; Kudriavtsev IuV; Medvedev AA; Razumov SV; Kochetov SA
    Urologiia; 2004; (5):10-6. PubMed ID: 15560155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters.
    Bosch RJ; Griffiths DJ; Blom JH; Schroeder FH
    J Urol; 1989 Jan; 141(1):68-72. PubMed ID: 2462067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical studies in canine prostatic hyperplasia--effect of antiandrogen.
    Murakoshi M; Ikeda R; Tagawa M; Nakayama T
    Tokai J Exp Clin Med; 1999 Jun; 24(2):77-83. PubMed ID: 10641996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benign hypertrophy of the prostate.
    Mogere RM; Baraza R
    East Afr Med J; 2007 Dec; 84(12):553-5. PubMed ID: 18402305
    [No Abstract]   [Full Text] [Related]  

  • 30. [New conservative therapeutic approaches in benign prostatic hyperplasia].
    Schulze H; Berges R; Paschold K; Senge T
    Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of the long-term effect of anti-androgen therapy by sonometrics in patients with benign prostatic hypertrophy].
    Kimura A; Higuchi T
    Nihon Hinyokika Gakkai Zasshi; 1988 Oct; 79(10):1697-702. PubMed ID: 2471862
    [No Abstract]   [Full Text] [Related]  

  • 32. Synergic inhibitory effects of the aromatase inhibitor 1-methyl-androsta-1, 4-diene-3, 17-dione and the antiandrogen cyproterone acetate on androstenedione-induced hyperplastic effects in the prostates of castrated dogs.
    Habenicht UF; el Etreby MF
    Prostate; 1987; 11(2):133-43. PubMed ID: 2444953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Benign prostatic hyperplasia: treatment options in the dog].
    Renggli M; Padrutt I; Michel E; Reichler I
    Schweiz Arch Tierheilkd; 2010 Jun; 152(6):279-84. PubMed ID: 20533201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of cyproterone acetate in comparison to flutamide on the ventral prostate of adult male castrated Copenhagen-Fisher rats and on Dunning R-3327 H tumors.
    Donn F; Becker H; Klosterhalfen H; Klein H
    Andrologia; 1989; 21(5):462-7. PubMed ID: 2530921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current therapy of benign prostatic hypertrophy].
    Rist M
    Schweiz Rundsch Med Prax; 1986 Jul; 75(29):875-6. PubMed ID: 2426754
    [No Abstract]   [Full Text] [Related]  

  • 36. Smooth muscle cell of the canine prostate in spontaneous benign hyperplasia, steroid induced hyperplasia and estrogen or tamoxifen treated dogs.
    Bruengger A; Bartsch G; Hollinger BE; Holly B; Rohr HP
    J Urol; 1983 Dec; 130(6):1208-10. PubMed ID: 6196492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of benign prostatic hyperplasia with antiandrogens (cyproterone acetate) and antiestrogens (tamoxifen)].
    Giovannoni S; Tassi B
    Minerva Urol Nefrol; 1987; 39(4):363-8. PubMed ID: 2453929
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibition of experimentally induced mouse prostatic hyperplasia by castration or steroid antagonist administration.
    Sikes RA; Thomsen S; Petrow V; Neubauer BL; Chung LW
    Biol Reprod; 1990 Aug; 43(2):353-62. PubMed ID: 1696141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Can mepartricin be considered an antiandrogenic drug?].
    Lubrano C; Bianchi P; Verna T
    Minerva Urol Nefrol; 1992; 44(2):113-6. PubMed ID: 1384153
    [No Abstract]   [Full Text] [Related]  

  • 40. [Hormonal therapy of benign prostatic hyperplasia].
    Horninger W; Bartsch G
    Urologe A; 1995 Jan; 34(1):9-15. PubMed ID: 7533450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.